- Earnings & Valuation
- Insider & Institutional Ownership
- Analyst Recommendations
- Risk & Volatility
- About PetVivo
- About Beyond Air
PetVivo (OTCMKTS:PETV – Get Rating) and Beyond Air (NASDAQ:XAIR – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.
Earnings & Valuation
This table compares PetVivo and Beyond Air’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Beyond Air||$870,000.00||196.66||-$43.18 million||($1.79)||-3.20|
PetVivo has higher earnings, but lower revenue than Beyond Air. Beyond Air is trading at a lower price-to-earnings ratio than PetVivo, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
12.9% of PetVivo shares are owned by institutional investors. Comparatively, 16.5% of Beyond Air shares are owned by institutional investors. 24.9% of PetVivo shares are owned by insiders. Comparatively, 14.7% of Beyond Air shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares PetVivo and Beyond Air’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and recommmendations for PetVivo and Beyond Air, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Beyond Air has a consensus target price of $21.50, indicating a potential upside of 275.87%. Given Beyond Air’s higher possible upside, analysts plainly believe Beyond Air is more favorable than PetVivo.
Risk & Volatility
PetVivo has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Beyond Air has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500.
Beyond Air beats PetVivo on 7 of the 13 factors compared between the two stocks.
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company’s pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.